-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Production Process of methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate involves a multi-step synthetic process that involves a variety of chemical reactions and purification steps.
The synthesis of this compound, which is also known as Cyclosporine A, typically begins with the synthesis of the cyclopropane ring, which is a key structural element of the molecule.
This is typically accomplished through a series of reactions that involve the formation of a cyclopropanecarbaldehyde intermediate, followed by reduction to form the cyclopropane ring.
Next, the synthesis of the quinoxaline ring is typically accomplished through a series of reactions that involve the formation of a quinoxaline-1,2-dicarbaldehyde intermediate, followed by reduction to form the quinoxaline ring.
The tert-butyl and methoxy groups are then introduced through a series of intermediate steps, followed by the introduction of the carboxylate group at the end of the synthesis process.
The production process of Cyclosporine A is a complex and multi-step synthesis that involves a variety of chemical reactions and purification steps.
The final product is a white to off-white powder that is soluble in organic solvents and has a melting point in the range of 160-165°C.
The molecule has a complex and highly functionalized structure, with a wide range of pharmaceutical properties and potential therapeutic applications.
Overall, the production process of methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate is a challenging and complex synthetic process that requires a high degree of technical expertise and specialized equipment.
However, the final product has the potential to provide important therapeutic benefits for a wide range of diseases and conditions.